India vs Big Pharma: Compulsory licence for leukaemia drug sought
'Compulsory licence verdict a triumph for humanity'
Experts believe that this case will set a precedent for all future legal tangles between Big Pharma and the country as a marker of how cases pertaining to drug patents will be played out in the country.
Novartis not optimistic about Supreme Court verdict
Leading lawyer calls India's pharma sector 'hip and hapenning'
Judges tell Novartis at Rs 1.2 lakh a month, drugs too expensive for them!
Novartis claims to have distributed free drugs worth Rs 7,500 cr
SC asks Novartis to reduce drug price - again!
Intellectual property board hears Bayer vs compulsory licencing case, verdict awaited
Cancelling compulsory license won't be against public interest: Bayer
"Novartis win will have an adverse impact on the access to treatment"
Pathbreaking case - India Vs Big Pharma - in Supreme Court tomorrow
India vs Big Pharma: Compulsory licence for leukaemia drug sought
'Compulsory licence verdict a triumph for humanity'
Experts believe that this case will set a precedent for all future legal tangles between Big Pharma and the country as a marker of how cases pertaining to drug patents will be played out in the country.
Novartis not optimistic about Supreme Court verdict
Leading lawyer calls India's pharma sector 'hip and hapenning'
Judges tell Novartis at Rs 1.2 lakh a month, drugs too expensive for them!
Novartis claims to have distributed free drugs worth Rs 7,500 cr
SC asks Novartis to reduce drug price - again!
Intellectual property board hears Bayer vs compulsory licencing case, verdict awaited
Cancelling compulsory license won't be against public interest: Bayer
"Novartis win will have an adverse impact on the access to treatment"
Pathbreaking case - India Vs Big Pharma - in Supreme Court tomorrow
